Recent clinical data surrounding this compound, specifically the 120mg formulation ZPHC ZPHC, reveal a impressive impact on body mass loss and linked metabolic factors. Experts believe that this dual agonist , affecting both GLP-1 and GIP systems, could represent a major advance in